Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

39.64 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Harmony Biosciences, The No. 3 Biotech, Just Topped Forecasts; But Concerns Persist ↗

February 21, 2023

The company offered neither financial guidance nor plans for a new CEO.

Via Investor's Business Daily

Big Retailers Report ↗

February 21, 2023

Good Morning Everyone! Customers are setting banks on fire in Lebanon because they can’t get their money out. Inflation is at +170%. This is what a currency collapse looks like:

Via Benzinga

Harmony Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

February 21, 2023

From Harmony Biosciences

Via GlobeNewswire

Alkermes Stock Sees Rising Relative Price Strength ↗

February 17, 2023

The Relative Strength (RS) Rating for Alkermes stock entered a new percentile Friday, with an increase from 79 to 86.

Via Investor's Business Daily

With This Big Transition Ahead, Is Novavax a Buy? ↗

January 12, 2023

Novavax stock sank 92% last year.

Via The Motley Fool

4 Analysts Have This to Say About Harmony Biosciences ↗

November 03, 2022

Within the last quarter, Harmony Biosciences (NASDAQ:HRMY) has observed the following analyst ratings:

Via Benzinga

Where Harmony Biosciences Stands With Analysts ↗

October 14, 2022

Analysts have provided the following ratings for Harmony Biosciences (NASDAQ:HRMY) within the last quarter:

Via Benzinga

Anavex Life Sciences Stock Shows Improved Price Strength Rating ↗

February 07, 2023

Anavex Life Sciences stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 68 to 75.

Via Investor's Business Daily

The 7 Best Biotech Stocks to Buy for February 2023 ↗

February 07, 2023

Following the wave of red ink last year, astute investors should target the best biotech stocks to buy this month for strong growth potential.

Via InvestorPlace

7 Healthcare Stocks That Will Be Big Winners in 2023 ↗

January 31, 2023

Healthcare stocks had a strong 2022 which will continue throughout 2023 making these picks ones to consider.

Via InvestorPlace

If You Invested $1,000 in Novavax In 2020, This Is How Much You Would Have Today ↗

January 13, 2023

The stock has gone on a wild ride over the past few years.

Via The Motley Fool

2 Biotechs Making Waves With A Single Product in their Pipeline

January 11, 2023

Catalyst Pharmaceuticals and Harmony Bioscience each have a single product in their respective pipelines, and both show incredible promise.

Via MarketBeat

6 Analysts Have This to Say About Harmony Biosciences ↗

August 03, 2022

Harmony Biosciences (NASDAQ:HRMY) has observed the following analyst ratings within the last quarter:

Via Benzinga

Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

January 09, 2023

Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash.

Via Benzinga

NVAX Stock Alert: What to Know as Novavax Names New CEO ↗

January 09, 2023

Although a change at the top boosted sentiment for Novavax, the harsh reality is that NVAX stock faces a mountain of worries.

Via InvestorPlace

Moderna Stock Shows Surprising Strength; Key Rating Upgraded ↗

December 14, 2022

See if Moderna stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day average.

Via Investor's Business Daily

BeiGene Stock Shows Market Leadership With Jump To 82 RS Rating ↗

December 08, 2022

On Thursday, China-based BeiGene stock cleared that desired 80-plus benchmark, with a jump to 82 from 77 a day earlier.

Via Investor's Business Daily

Xenon Pharmaceuticals Stock Scores Rising Relative Strength Upgrade ↗

November 29, 2022

Xenon Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 92 Tuesday, up from 89 a day earlier.

Via Investor's Business Daily

BioCryst Pharmaceuticals Stock Sees RS Rating Rise To 84 ↗

November 11, 2022

The Relative Strength (RS) Rating for BioCryst Pharmaceuticals stock climbed into a new percentile Friday, with a rise from 64 to 84.

Via Investor's Business Daily

Looking Into Harmony Biosciences's Return On Capital Employed ↗

November 09, 2022

According to Benzinga Pro, during Q3, Harmony Biosciences (NASDAQ:HRMY) earned $87.94 million, a 273.73% increase from the preceding quarter. Harmony Biosciences also posted a total of $117.21 million...

Via Benzinga

Gartner, Sony, Uber And Other Big Gainers From Tuesday ↗

November 02, 2022

U.S. stocks closed lower on Tuesday, with the Nasdaq Composite dropping around 100 points. Here is the list of some big stocks recording gains in the previous session.

Via Benzinga

Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday ↗

November 02, 2022

Gainers

Via Benzinga

Harmony Biosciences Holdings, Inc. (HRMY) Q3 2022 Earnings Call Transcript ↗

November 01, 2022

HRMY earnings call for the period ending September 30, 2022.

Via The Motley Fool

Why IBD 50 Stock Harmony Biosciences Flew To The High End Of Its Buy Zone ↗

November 01, 2022

The third-quarter beat, alone, wasn't enough to drive the positive stock movement.

Via Investor's Business Daily

Recap: Harmony Biosciences Q3 Earnings ↗

November 01, 2022

Harmony Biosciences (NASDAQ:HRMY) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Earnings Harmony Biosciences...

Via Benzinga

Harmony Biosciences Reports Third Quarter 2022 Financial Results and Business Updates

November 01, 2022

From Harmony Biosciences

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2022 ↗

October 14, 2022

Upgrades

Via Benzinga

Domino's Pizza To Rally 20%? Here Are 5 Other Price Target Changes For Friday ↗

October 14, 2022

Wedbush raised Domino's Pizza, Inc. (NYSE: DPZ) price target from $370 to $400. Wedbush analyst Nick Setyan maintained an Outperform rating on the stock. Domino's shares rose 10.4% to close at $333.26...

Via Benzinga

Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review ↗

August 05, 2022

The Nasdaq and small caps rose while the S&P 500 is hitting resistance.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022 ↗

August 03, 2022

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.